P174 A higher prevalence of onychomycosis in abnormal appearing nails in psoriatics compared to non-psoriatics: A multicenter study

Gupta, Abhaya; Lynde, Charles; Jain, Hem C.

doi:10.1016/s0926-9959(97)89646-8

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, the projected prevalence of onychomycosis in the general immunocompetent population of Canada is 6.9%. 39 For comparison, the projected prevalence of onychomycosis in diabetics 44 and psoriatics 45 is 32.3% and 11.9%, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…The presence of onychomycosis in normal appearing nails indicates that the disease has been detected mycologically at an early stage prior to the development of clinically abnormal nails. For comparison, the corresponding figures of onychomycosis in clinically normal nails in psoriatics 45 and diabetics 44 were 0.7% and 3.0%, respectively. Thus, HIV‐positive patients may have a higher prevalence of onychomycosis that develops at a relatively young age compared to the immunocompetent population.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Epidemiology and prevalence of onychomycosis in HIV‐positive individuals

Gupta¹,

Taborda²,

Taborda³

et al. 2000

Int J Dermatology

142

117

View full text Add to dashboard Cite

The prevalence of onychomycosis in HIV-positive individuals in the sample of 500 patients was 23.2%. In the Canadian (n=400) and Brazilian (n=100) samples, the corresponding figures were 24% and 20%, respectively, with the predominant causative organisms being dermatophytes. The projected prevalence of onychomycosis in HIV-positive Canadians is 19.9%. Predisposing factors include a CD4 count of approximately 370, a positive family history of onychomycosis, a history of tinea pedis, and walking barefoot around pools. Onychomycosis can be symptomatic, a source of embarrassment, and a potential cause of morbidity.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Epidemiology and prevalence of onychomycosis in HIV‐positive individuals

Gupta¹,

Taborda²,

Taborda³

et al. 2000

Int J Dermatology

142

117

View full text Add to dashboard Cite

show abstract

“…Despite adequate therapy and mycological cure, the nail may still appear dystrophic, with residual changes consistent with a comorbid pathology such as psoriasis or trauma. Patients with psoriasis, for example, have a higher prevalence of onychomycosis compared to the normal population of the same age and sex 21 …”

Section: Onychomycosis: Treatment Failure?mentioning

confidence: 99%

Onychomycosis of toenails: Orthopaedic and podiatric considerations

Murray

Dawber

2002

Aust J Dermatology

View full text Add to dashboard Cite

Onychomycosis is common, affecting approximately 5% of the population, and is the most resistant form of superficial fungal infection. Dermatologists often view the nail apparatus in static terms and unfortunately give little consideration to the functional aspects of the digit. In the case of toenails, it is important to consider the toes and foot as a closely integrated functional unit. It is essential that in any case of onychomycosis or onychodystrophy that, as clinicians, we have an understanding of foot dynamics, of structure/function relationships and of the implications of orthopaedic/podiatric factors when evaluating cases of nail dystrophy. When confronted with cases of possible onychomycosis, we must adopt a systematic and sometimes multidisciplinary approach in the evaluation and management of these patients to improve patient outcomes.

show abstract

“…4.0-7.4) compared with patients in whom there had been no trauma to the nails [4]. Based on a survey of 561 patients with psoriasis [5] and 550 patients with diabetes [6], it is estimated that 12% of psoriatic patients and approximately one-third of diabetics would be expected to have onychomycosis.…”

Section: Introductionmentioning

confidence: 99%

The new oral antifungal agents for onychomycosis of the toenails

Gupta

Shear

1999

Acad Dermatol Venereol

View full text Add to dashboard Cite

Itraconazole, terbinafine and fluconazole have been used approximately 100 million times to treat superficial mycoses. These agents are more effective than the traditional antimycotics for the treatment of pedal onychomycosis; furthermore, the new agents have a broader spectrum of action than griseofulvin. In general, itraconazole, terbinafine and fluconazole have a favorable adverse-effects profile with drug interactions that are usually predictable and manageable. The new oral antifungal agents have a high benefit-to-risk ratio when used to treat toenail onychomycosis.

show abstract

P174 A higher prevalence of onychomycosis in abnormal appearing nails in psoriatics compared to non-psoriatics: A multicenter study

Cited by 3 publications

References 0 publications

Epidemiology and prevalence of onychomycosis in HIV‐positive individuals

Epidemiology and prevalence of onychomycosis in HIV‐positive individuals

Onychomycosis of toenails: Orthopaedic and podiatric considerations

The new oral antifungal agents for onychomycosis of the toenails

Contact Info

Product

Resources

About